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Efficacy and safety of green laser photocoagulation
for threshold retinopathy of prematurity
INTRODUCTION
According to the World Health Organization, 500,000 children go blind
every year, and half of these cases are preventable. In middle income
countries, retinopathy of prematurity (ROP) is among the leading causes
of blindness, the incidence of which can be reduced through availability
and affordability of screening and curative services(1-2).
Retinopathy of prematurity is a disease that affects the immature vas-
culature in the eyes of premature babies. It can be mild with no visual defects,
or it may become aggressive with new blood vessel formation (neovascula-
rization) and progress to retinal detachment and blindness. As smaller and
younger babies are surviving, the incidence of ROP has increased(3-4).
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Purpose: To report the efficacy and safety of green laser photocoa-
gulation for threshold retinopathy of prematurity (ROP). Methods: We
reviewed the clinical records of the neonates who had undergone green
laser photocoagulation for threshold ROP at the Federal University of
Pernambuco in Brazil between January 2004 and January 2006. All
procedures were conducted with local anesthetic drops. The neonates
were monitored throughout the procedure by a neonatologist. A fre-
quency-doubled solid state laser, diode-pumped, with 532 nm wave-
length was used. The presence of tunica vasculosa lentis or cataract were
excluded before laser treatment. The following preoperative data were
obtained for each patient: age, birth weight and the grade of ROP.
Postoperative data included complications associated with the laser
treatment, grade of ROP and evaluation whether further surgery was
necessary due to failure of laser photocoagulation. Results: Twenty-two
neonates underwent photocoagulation with green laser for threshold
ROP. A total of 31 eyes were included in the study. The mean gestational
age was 30 ± 3 weeks and the mean birth weight was 1120 ± 490 g. Re-
gression of the disease after laser therapy was observed in 30 eyes (96.7%).
Despite treatment one eye presented stage 4A. Only 7 eyes required
repetitive laser therapy. No adverse effects such as burning anterior
segment tissues or bleeding in the anterior chamber occurred. No poste-
rior segment side-effects were observed. Cataract formation was not
observed at the last follow-up examination. Conclusions: Green laser
photocoagulation remains an effective and safe alternative to red laser
photocoagulation and to cryotherapy in the treatment of threshold ROP.
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In the Cryotherapy Study for ROP(5), and Early Treatment
ROP Study(6) excellent results were achieved if ROP was
treated with either indirect laser photocoagulation or cryo-
therapy.
Laser therapy can be delivered using red (diode) or green
(argon or frequency-doubled solid state laser diode-pumped)
wavelength. The risk of acquired cataract after transpupillary
laser photocoagulation for ROP is low(7). However, some au-
thors report that red laser photocoagulation may be safer than
argon laser photocoagulation(8-9).
The aim of this study was to report the efficacy and safety
of green laser photocoagulation for threshold ROP.
METHODS
We reviewed the clinical records of the neonates who had
undergone green laser photocoagulation for threshold ROP
at the Federal University of Pernambuco in Brazil between
January 2004 and January 2006. Threshold ROP was determi-
ned as five or more contiguous or eight cumulative 30-degree
sectors of stage 3 ROP in the presence of ‘plus’ disease(5). The
study protocol was approved by the Ethics Committee
(CONEP 0146.0.172.000-06).
All procedures were conducted with local anesthetic
drops (Anestalcon®, Alcon). The neonates were monitored
throughout the procedure by a neonatologist. Tight scatter of
laser application was performed, with a burn diameter bet-
ween burns, from the area posterior to the ridge up to the ora
serrata. The avascular retina was treated with moderate white
burns. A frequency-doubled solid state laser, diode-pumped,
with 532-nm wavelength (Visulas 532® Carl Zeiss) was used.
The presence of tunica vasculosa lentis or cataract were ex-
cluded before laser treatment.
The following preoperative data were obtained for each
patient: age, birth weight and the grade of ROP. Postoperative
data included complications associated with the laser treat-
ment, grade of ROP and evaluation whether further surgery was
necessary due to failure of laser photocoagulation. Follow-ups
to assess the anatomic result were performed weekly until ROP
regression occurred. Unfavourable outcomes were assessed in
accordance with the Cryotherapy Study for ROP(5).
 RESULTS
During the period from January 2004 to January 2006,
twenty-two neonates underwent photocoagulation with green
laser for threshold ROP. A total of 31 eyes were included in the
study. The mean gestational age was 30 ± 3 weeks (range 24-
32 weeks) and the mean birth weight was 1120 ± 490 g (range
595-1955 g). The average laser power used was 150 mW, with
duration of 0.1 s and the mean number of burns was 320 per
eye. The mean follow-up time was 8 ± 3 months.
Signs of ROP regression after laser therapy were observed
at the first week in 24 eyes (77.4%). Only 7 eyes (22.6%) required
repetitive laser therapy, with evidence of disease regression
one week later. Six weeks after treatment there was total ROP
regression in 30 eyes (96.7%). Despite treatment one eye
presented stage 4A.
No adverse effects such as burns in anterior segment tis-
sues or bleeding in the anterior chamber occurred. No poste-
rior segment side-effects were observed. Cataract formation
was not observed at the last follow-up examination.
DISCUSSION
Currently, laser treatment is the best therapy available for
threshold ROP. It causes less effusion than cryotherapy and has at
least as good results from an anatomical and visual standpoint(10-12).
In the not so distant future, it may be that pharmacologic therapy
will be possible(7,13-16). Besides the immediate short-term results it
seems that laser therapy may also be beneficial in respect to
longterm functional and visual outcome. Eyes treated with
cryotherapy have been found to be significantly more myopic
than those treated with laser photocoagulation(10-12,17). Although
laser has definite advantages, cryotherapy can be considered as an
alternative modality of treatment in developing countries due to
economic reasons(10-12).
Laser complications of the anterior segment can include
burns to the cornea, iris and tunica vasculosa lentis with
induction of cataract, anterior ischemia, bleeding into the
anterior and posterior chambers(12,18-19). In our study none of
these complications occurred after laser application. Minor
spot bleeding at the ridge may occur but these hemorrhages
are reabsorbed spontaneously. Laser treatment showed favo-
rable results in our study, inducing regression of threshold
ROP in 96.7% of all treated eyes.
It should be noted that cataracts, as well as anterior seg-
ment ischemia, can be observed after laser treatment with
either green or red wavelength(7). The incidence of cataract
formation with laser photocoagulation is low and may be
more likely to occur when persistent hyaloidal vessels are
present on the lens(8,20-21).
The red laser machine is cheaper but the green laser is less
painful(8-9,22). There are many public hospitals in Brazil that
had bought green laser, but do not have a red diode laser or an
adequate cryotherapy machine. In these institutions green
laser can become a good option to treat most cases of ROP.
The lack of controls and the lack of randomization limit
the results of our study. Nevertheless our findings are encou-
raging with respect to the efficacy and safety of green laser
photocoagulation as a valuable alternative to red laser and to
cryotherapy.
CONCLUSION
Green laser photocoagulation remains an effective and
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safe alternative to red laser photocoagulation and to cryothe-
rapy in the treatment of threshold ROP. Randomized clinical
trials are necessary to further validate these results.
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RESUMO
Objetivos: Avaliar a eficácia e segurança da fotocoagulação
com laser verde na retinopatia da prematuridade (ROP) li-
miar. Métodos: Foram revisados prontuários dos neonatos
submetidos à fotocoagulação com laser verde para ROP li-
miar, na Universidade Federal de Pernambuco, entre janeiro
2004 e janeiro 2006. Tratamento foi realizado com anestesia
tópica, sob monitorização de neonatologistas. Foi utilizado
laser verde de estado sólido com diodo de freqüência dobra-
da de 532 nm. Presença de túnica vasculosa lentis ou catarata
foi excluída antes do tratamento. Foram obtidos os seguintes
dados pré-operatórios: idade, peso ao nascer e estágio da
ROP. Dados pós-operatórios incluíram complicações asso-
ciadas com o tratamento, estágio da ROP e avaliação da ne-
cessidade de cirurgia por falha do tratamento com fotocoagu-
lação. Resultados: Vinte e dois neonatos foram submetidos à
fotocoagulação com laser verde para ROP limiar. Um total de
31 olhos foi incluído no estudo. A idade gestacional média
foi de 30 ± 3 semanas e a média do peso ao nascer foi de 1120
± 490 g. Regressão da doença após terapia com laser foi
observada em 30 olhos (96,7%). Apesar do tratamento um
olho evoluiu para estágio 4A. Apenas 7 olhos precisaram de
mais uma sessão de laser. Não houve efeitos adversos na
câmara anterior como queimaduras ou sangramentos. Tam-
bém não foram observados efeitos colaterais no segmento
posterior. Formação de catarata não foi observada até o final
do acompanhamento. Conclusões: A fotocoagulação com
laser verde é uma alternativa efetiva e segura à fotocoagu-
lação com laser vermelho e à crioterapia para o tratamento da
ROP limiar.
Descritores: Retinopatia da prematuridade; Coagulação por
laser; Resultado de tratamento
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